ClinicalTrials.gg

Obesity clinical trials

Its pipeline, or its studies — you choose. Free with an account during the beta.

The registry lists 11,543 studies for Obesity across more than 10 countries. 2,047 are recruiting or about to start. 7,602 of them are mainly about Obesity (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-16. Counting its 7 narrower conditions too, such as Pediatric Obesity: 13,407 studies, 2,357 open.

ClinicalTrials.gov finds 15,187 studies for Obesity. How that becomes 11,536 here

This page counts the studies the registry files under Obesity, and those it files under no condition that list Obesitythemselves. Each study its search finds is placed by how the registry filed it and by the conditions it lists. ClinicalTrials.gov counts as of Nov 15, 2026. How condition pages count

  1. 15,187Found by its condition searchIt reads the conditions a study lists and their synonyms, and also titles and keywords.
  2. −1,860Filed under a narrower condition, counted on its own pagePediatric Obesity 780 · Obesity, Morbid 669 · Obesity, Abdominal 176 · Prader-Willi Syndrome 110 · Obesity Hypoventilation Syndrome 61 · Pregnancy in Obesity 34 · 1 more
  3. −142List Obesity as a condition, but the registry did not file them under itMost often written as “Sarcopenic Obesity” (31), “Obesity Prevention” (23), and “Hypothalamic Obesity” (15). The registry filed them under other conditions only, most often Motor Activity (18) and Sexual Infantilism (15).
  4. −1,649Match it another way500 name it in the title, 36 in a keyword, and 1,113 by a synonym or other text the search reads.
  5. 11,536The count on this page125 of them list Obesity in their own words; the registry filed them under no condition.

Status

Completed
7,201
Recruiting
1,342
Status unknown
1,012
Not yet recruiting
595
Active, not recruiting
595
Terminated
418

Phase

Phase 2
862
Phase 1
743
Phase 3
605
Phase 4
503
Early Phase 1
108

Where

United States
4,822
China
600
Canada
574
France
475
United Kingdom
453
Spain
388

Who develops what

Add Obesity to watchlistPro · free during the betaEvery Monday by email · turn it off any time

Every program with a company-led study here in the last two years, whatever its size: 191 programs from 91 companies, 176 with this as their studies’ main aim; 37 with a live phase 3 study; 86 primary completions in the next 12 months. Compare Eli Lilly, Novo Nordisk and AstraZeneca here →

Comparator & background therapies

What other companies’ phase 2+ studies give as the comparator or the background here (its leading trial sponsor and partners left out): a sign of what new drugs are measured against, not by itself the standard of care, its prescriptions or its market.

DrugLeading trial sponsor · rightsCompanies, last 5 years
SemaglutideRecent, repeated
Evidence
  • NCT07866066 · Amgen · Phase 3 · live · comparator · “Semaglutide” · registered Oct 2026
  • NCT07845500 · Pfizer · Phase 3 · live · comparator · “Semaglutide” · registered Sep 2026
  • NCT07812597 · Beijing QL Biopharmaceutical Co.,Ltd · Phase 2 · live · comparator · “semaglutide” · registered Aug 2026
  • NCT07754045 · Lumos Pharma, Inc. · Phase 2 · live · background · “Semagludtide” · registered Jul 2026
  • NCT07622810 · Carnot Laboratories · Phase 3 · live · comparator · “Semaglutide” · registered May 2026
Novo Nordisk A/S89% of its industry studiesUS: Novo Nordisk A/S (FDA 2019)EU: Novo Nordisk A/S (EMA 2018)2125 studies
TirzepatideRecent, repeated
Evidence
  • NCT07845500 · Pfizer · Phase 3 · live · comparator · “Tirzepatide” · registered Sep 2026
  • NCT07521631 · Huadong Medicine Co., Ltd. · Phase 2 · live · comparator · “Tirzepatide” · registered Mar 2026
  • NCT07463846 · Alnylam Pharmaceuticals · Phase 2 · live · comparator · “Tirzepatide” · registered Mar 2026
  • NCT07245771 · Ikaria Bioscience Pty Ltd · Phase 2 · live · background · “Tirzepatide” · registered Sep 2025
  • NCT07000955 · Innovent Biologics, Inc. · Phase 2 · live · comparator · “Tirzepatide” · registered May 2025
Eli Lilly and Company96% of its industry studiesUS: Eli Lilly and Company (FDA 2022)EU: Eli Lilly and Company (EMA 2022)1314 studies
OrlistatRecent, repeated
Evidence
  • NCT06993428 · Empros Pharma AB · Phase 2 · live · comparator · “Alli® 60 mg” · registered May 2025
  • NCT05934110 · Empros Pharma AB · Phase 2 · live · comparator · “Conventional orlistat 120 mg,” · registered May 2023
  • NCT05579249 · Novo Nordisk A/S · Phase 4 · comparator · “Orlistat” · registered Oct 2022
  • NCT00422058 · Novo Nordisk A/S · Phase 2 · comparator · “orlistat” · registered Jan 2007
GlaxoSmithKline27% of its industry studiesUS: CHEPLAPHARM (FDA 1999) + 1 otherEU: CHEPLAPHARM Arzneimittel GmbH (EMA 1998) + 1 other23 studies

9 more in limited or earlier use — sign in to see them, free.

Programs

“Meets, by arms” reads each study’s arms: vs its arm against the therapy’s; + X vs a combination against it; added to it plus the therapy against the therapy; studied with given together only. The next primary completion is the next phase-3 study’s when there is one.

In phase 3Company
TirzepatideApproved: US 2022 · EU 2022☆ Track8 live phase-3 studies: NCT05556512, NCT06937086, NCT06937099Eli Lilly and Company
retatrutide☆ Track5 live phase-3 studies: NCT07232719, NCT07035093, NCT06662383Eli Lilly and Company
ribupatide☆ Track3 live phase-3 studies: NCT06994650, NCT07285902, NCT06974851Jiangsu HengRui Medicine Co., Ltd.
IN-B00009☆ Track1 live phase-3 study: NCT07192263HK inno.N Corporation
maridebart cafraglutide☆ Track11 live phase-3 studies: NCT07871409, NCT07575399, NCT07866066Amgen

The 5 in phase 3 with the nearest primary completion, of 191 programs — sign in to see the whole list, free: filter by phase and aim, sort by late development, direct comparisons or the next primary completion.

Primary completion in the next 12 months (86)

Live phase 2 and 3 studies of these programs. Primary completion is when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced.

  • Nov 2026 est.Tirzepatide · Eli Lilly and Company · Phase 3 named, not the main aimNCT06914895 A Study of Tirzepatide (LY3298176) Compared With Placebo in Adults With Type 1 Diabetes and Obesity or Overweight — primary endpoint: Change from Baseline in Hemoglobin A1c (HbA1c) · 905 enrolled
  • Nov 2026 est.Tirzepatide · Eli Lilly and Company · Phase 3 named, not the main aimNCT06962280 A Long-Term Study of Tirzepatide (LY3298176) in Adults With Type 1 Diabetes and Obesity or Overweight — primary endpoint: Change from Baseline in Hemoglobin A1c (HbA1c) · 465 enrolled
  • Nov 2026 est.retatrutide · Eli Lilly and Company · Phase 3 main aimvs TirzepatideNCT06662383 A Study of Retatrutide (LY3437943) Compared to Tirzepatide (LY3298176) in Adults Who Have Obesity — primary endpoint: Percent Change from Baseline in Body Weight · 800 enrolled

83 more — sign in to see them all, free.

Read from ClinicalTrials.gov, industry-led studies. Main aim: this is the study’s judged main condition; named, not the main aim: the sponsor names it, the study is about something else; registry mapping only: only the registry’s mapping put it here. Leading trial sponsor is the company leading the most industry studies of a drug, a measure of trial activity, not of rights. US and EU rights, and Approved: from the regulators’ records (FDA’s Drugs@FDA via openFDA; EMA’s medicines data) — the holder of a marketed or authorized original, generics and other companies’ versions; not rights elsewhere, nor approval for this condition. Phase 4 trial recorded, where neither lists it: a phase 4 study exists somewhere. Not read yet: labels by indication, exclusivity, licenses, line of therapy, academic comparators, sales.

What is being tested here

Drugs under test in Obesity studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug classes tested here GLP-1 receptor agonists 131 open · Mineralocorticoid receptor antagonists (MRAs) 6 open · SGLT2 inhibitors 5 open · Opioid antagonists 4 open · Stimulants 3 open

Coming up

852studies finish main data collection within a year47 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

The 10 nearest, phase 3 first

Who these studies take

Of the 1,342 Obesity studies recruiting now, 377 (28%) set no upper age limit and 861 (64%) stop at 75 or younger. 168 (13%) take children under 18. 134 (10%) are for women only and 18 (1%) for men only; 489 (36%) take healthy volunteers.

Recruiting studies that take each age, of 1,342
AgeWomenMen
1090 (7%)84 (6%)
181,018 (76%)935 (70%)
301,117 (83%)1,026 (76%)
401,126 (84%)1,037 (77%)
501,087 (81%)1,018 (76%)
65902 (67%)860 (64%)
75575 (43%)545 (41%)
85417 (31%)391 (29%)

Across all 11,543 studies, recruiting or not: 70% stop at 75 or younger and 56% at 65; 16% take children; 14% are for women only and 5% for men only; 47% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Obesity studies take

Of 440 phase 1 interventional studies under Obesity, half reached primary completion within 11 months of starting, counting those still running.

Start to primary completionEvery sponsorIndustryNon-industry
Phase 111 mo6–24 · 440 studies9 mo5–15 · 335 studies32 mo12–57 · 105 studies
Phase 1/227 mo14–36 · 62 studies—31 mo14–36 · 39 studies
Phase 216 mo10–35 · 307 studies12 mo8–18 · 176 studies35 mo15–57 · 131 studies
Phase 2/347 mo30–53 · 36 studies—47 mo30–53 · 33 studies
Phase 324 mo18–34 · 262 studies21 mo18–27 · 199 studies36 mo24–56 · 63 studies
Phase 431 mo15–51 · 210 studies—32 mo15–52 · 190 studies
Interventional, no phase22 mo9–42 · 3,853 studies13 mo6–27 · 163 studies23 mo10–43 · 3,690 studies
Observational39 mo17–96 · 839 studies25 mo9–45 · 46 studies40 mo17–106 · 793 studies

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

What changed recently

From the registry's own updates since Oct 18, 2026.

Started recruiting40

Show 35 more

Newly registered102

Show 45 more

and 52 more not listed

Studies

Recruiting first, then most recently updated. Showing 50 of 11,543. Browse all 11,543 → or search them.